Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.34 |
| ▸ | WDR5 | P61964 | 7/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31209934 | 0.91 | BRAF (0.38) | BRAFWDR5 | |
| SCHEMBL31209862 | 0.87 | BRAF (0.37) | BRAFWDR5 | |
| SCHEMBL31209085 | 0.87 | BRAF (0.34) | BRAFWDR5 | |
| SCHEMBL31208665 | 0.86 | WDR5 (0.36) | BRAFWDR5KRAS | |
| SCHEMBL31209747 | 0.86 | WDR5 (0.36) | BRAFWDR5KRAS | |
| SCHEMBL31209915 | 0.86 | BRAF (0.34) | BRAFWDR5 | |
| SCHEMBL31208949 | 0.86 | BRAF (0.34) | BRAFWDR5 | |
| SCHEMBL31209342 | 0.85 | BRAF (0.33) | BRAFWDR5 | |
| SCHEMBL31209426 | 0.85 | WDR5 (0.33) | BRAFWDR5KRAS | |
| SCHEMBL31208629 | 0.84 | PTPN11 (0.35) | KRASCREBBPSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | BRAF 10/4885WDR5 1928/4885KRAS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.